Pivotal readout
Sac-TMT Improves Overall Survival
In the 473-patient phase 3 TroFuse-015 trial, sac-TMT significantly improved overall survival versus physician's-choice therapy after at least two prior systemic treatments. The trial did not meet its progression-free survival endpoint; the response-rate improvement was nominal and not formally tested.
No new safety signals were reported. Merck plans to present detailed results at a medical meeting and share them with regulators; survival and response figures were not disclosed.
Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.